Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), a cancer/testis antigen expressed at varying levels in multiple solid tumors. We conducted a multicenter, dose-escalation, phase 1 trial in patients with relapsed/refractory metastatic solid tumors expressing MAGE-A4, including synovial sarcoma (SS), ovarian cancer and head and neck cancer ( NCT03132922 ). The primary endpoint was safety, and the secondary efficacy endpoints included overall response rate (ORR) and duration of response. All patients (N = 38, nine tumor…

• CP
  Cancer Prevention and Research Institute of Texas

  Awards: P30 CA016672, RP150535, CA016672
• OS
  Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
• SC
  Sylvester Comprehensive Cancer Center, University of Miami Health Systems
• NI
  National Institutes of Health

  Awards: NCI P30 CA016672, CA016672, NIH/NCI P30 CA016672, P30 CA016672
• UO
  University of Texas MD Anderson Cancer Center

  Awards: NIH/NCI P30 CA016672, NCI P30 CA016672, CA016672, P30 CA016672
• NC
  National Cancer Institute

  Awards: P30 CA016672, CA016672, NIH/NCI P30 CA016672, NCI P30 CA016672